Cassandra Otero, PA
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 28.7% of the total.
Across 93 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$411
- Lilly USA, LLC$172
- Pfizer$160
- Novo Nordisk$146
- Amarin Pharma, Inc.$137
- Nestle Healthcare Nutrition Inc.$88
- plus $317 from 10 others
What the payments were for
- Food & beverage$1,432100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 28 | $411 |
| Lilly USA, LLC | 9 | $172 |
| Pfizer | 8 | $160 |
| Novo Nordisk | 8 | $146 |
| Amarin Pharma, Inc. | 18 | $137 |
| Nestle Healthcare Nutrition Inc. | 5 | $88 |
| Bayer | 2 | $69 |
| Aimmune Therapeutics, Inc. | 3 | $49 |
| AstraZeneca | 3 | $47 |
| Exact Sciences | 2 | $33 |
| GSK | 2 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Optos, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
How this compares
$1,432 in reported general payments places this provider in the 75th percentile of 156 medical providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $92,372 |
| MounjaroTirzepatide | 43 | $50,734 |
| TrulicityDulaglutide | 25 | $25,740 |
| VraylarCariprazine Hcl | 13 | $21,054 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $15,888 |
| MyrbetriqMirabegron | 13 | $13,311 |
| JardianceEmpagliflozin | 12 | $9,949 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $9,810 |
| EliquisApixaban | 12 | $6,413 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $5,852 |
| Lisdexamfetamine Dimesylate | 24 | $4,114 |
| Levemir FlexpenInsulin Detemir | 12 | $3,429 |
| Gabapentin | 140 | $2,090 |
| Losartan Potassium | 164 | $1,674 |
| Levothyroxine Sodium | 180 | $1,611 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $146 | $92,37267 claims |
| Lilly USA, LLCMounjaro, Trulicity | $172 | $76,47368 claims |
| AbbVieVraylar, Synthroid | $411 | $21,72529 claims |
| GSKAnoro Ellipta | $27 | $15,88824 claims |
| PfizerEliquis | $160 | $6,41312 claims |
| AstraZenecaSymbicort | $47 | $5,85213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 156 medical providers in New Mexico.
Other medical in Belen
- Brenda PachecoAcoma$12K
- Paul TapiaAlbuquerque$7K
- Niki NinopoulosAlbuquerque$7K
- William BaconSanta Fe$6K
- Katie JoshiAlbuquerque$6K
- Loretta GonzalesAlbuquerque$5K
- Sarah East BrumanaRoswell$5K
- Ruben FrancoAlbuquerque$4K
- Bradford GwytherAlbuquerque$4K
- Danny MaysSanta Fe$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.